Sierra Oncology (NASDAQ:SRRA) Announces Earnings Results, Hits Expectations

Sierra Oncology (NASDAQ:SRRA) released its earnings results on Thursday. The biotechnology company reported ($0.20) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.20), Fidelity Earnings reports.

NASDAQ:SRRA remained flat at $$0.48 during mid-day trading on Friday. The company had a trading volume of 149,976 shares, compared to its average volume of 623,476. The firm’s 50 day simple moving average is $0.55. The stock has a market capitalization of $37.76 million, a P/E ratio of -0.64 and a beta of 1.24. Sierra Oncology has a one year low of $0.48 and a one year high of $2.17. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.07 and a quick ratio of 13.07.

A number of analysts recently weighed in on SRRA shares. ValuEngine upgraded Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded Sierra Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday.

Sierra Oncology Company Profile

Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.

Recommended Story: How to Profit and Limit Losses With Stop Orders

Earnings History for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.